Caseware UK (AP4) 2024.0.164 2024.0.164 2024-12-312024-12-3114No description of principal activity2024-01-01false18falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 04385775 2024-01-01 2024-12-31 04385775 2023-01-01 2023-12-31 04385775 2024-12-31 04385775 2023-12-31 04385775 c:Director4 2024-01-01 2024-12-31 04385775 d:FurnitureFittings 2024-01-01 2024-12-31 04385775 d:OfficeEquipment 2024-01-01 2024-12-31 04385775 d:CurrentFinancialInstruments 2024-12-31 04385775 d:CurrentFinancialInstruments 2023-12-31 04385775 d:Non-currentFinancialInstruments 2024-12-31 04385775 d:Non-currentFinancialInstruments 2023-12-31 04385775 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 04385775 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 04385775 d:Non-currentFinancialInstruments d:AfterOneYear 2024-12-31 04385775 d:Non-currentFinancialInstruments d:AfterOneYear 2023-12-31 04385775 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2024-12-31 04385775 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2023-12-31 04385775 d:ShareCapital 2024-12-31 04385775 d:ShareCapital 2023-12-31 04385775 d:SharePremium 2024-12-31 04385775 d:SharePremium 2023-12-31 04385775 d:RetainedEarningsAccumulatedLosses 2024-12-31 04385775 d:RetainedEarningsAccumulatedLosses 2023-12-31 04385775 c:OrdinaryShareClass1 2024-01-01 2024-12-31 04385775 c:OrdinaryShareClass1 2024-12-31 04385775 c:OrdinaryShareClass1 2023-12-31 04385775 c:OrdinaryShareClass4 2024-01-01 2024-12-31 04385775 c:OrdinaryShareClass4 2024-12-31 04385775 c:OrdinaryShareClass4 2023-12-31 04385775 c:FRS102 2024-01-01 2024-12-31 04385775 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 04385775 c:FullAccounts 2024-01-01 2024-12-31 04385775 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 04385775 e:PoundSterling 2024-01-01 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 04385775









EUROPA SCIENCE LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2024

 
EUROPA SCIENCE LIMITED
REGISTERED NUMBER: 04385775

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2024

2024
2023
Note
£
£

Fixed assets
  

Intangible assets
 5 
62,164
65,871

Tangible assets
 6 
2,129
4,709

  
64,293
70,580

Current assets
  

Debtors: amounts falling due within one year
 7 
446,266
455,120

Cash at bank and in hand
 8 
56,135
30,339

  
502,401
485,459

Creditors: amounts falling due within one year
  
(440,965)
(337,897)

Net current assets
  
 
 
61,436
 
 
147,562

Total assets less current liabilities
  
125,729
218,142

Creditors: amounts falling due after more than one year
 9 
(20,000)
(60,000)

Provisions for liabilities
  

Deferred tax
 11 
(16,073)
(17,645)

  
 
 
(16,073)
 
 
(17,645)

Net assets
  
89,656
140,497


Capital and reserves
  

Called up share capital 
 12 
3,020
3,020

Share premium account
  
59,250
59,250

Profit and loss account
  
27,386
78,227

  
89,656
140,497


Page 1

 
EUROPA SCIENCE LIMITED
REGISTERED NUMBER: 04385775
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2024

The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
Warren Lloyd Clark
Director

Date: 10 June 2025

The notes on pages 3 to 11 form part of these financial statements.

Page 2

 
EUROPA SCIENCE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1.


General information

Europa Science Limited (“the Company”) is a Limited company incorporated in the United Kingdom. The address of its registered office is 4 Signet Court, Swann Road, Cambridge, England, CB5 8LA.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

 
2.3

Turnover

Turnover comprises income recognised by the company in respect of the publishing of scientific and technical periodicals and associated activities supplied during the year, exclusive of Value Added Tax.

 
2.4

Operating leases

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

 
2.5

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.6

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

Page 3

 
EUROPA SCIENCE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.7

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.8

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
2.9

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

Amortisation is provided at the following rates:
Intangibles - 33% per annum over 3 years.

Page 4

 
EUROPA SCIENCE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2.Accounting policies (continued)

 
2.10

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives.

Depreciation is provided on the following basis:

Fixtures & fittings
-
25%
reducing balance
Office equipment
-
33%
straight line

 
2.11

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.12

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.13

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 5

 
EUROPA SCIENCE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

3.


Judgments in applying accounting policies and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the amounts reported for assets and liabilities as at the date of the Income Statement and the amounts reported for revenues and expenses during the year.
Critical accounting estimates and assumptions
The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amount of the assets and liabilities within the next financial year are addressed below.
Useful economic lives and residual values of non financial assets
The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are reassessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, economic utilization and the physical condition of the assets. See note 9 for the carrying amount of the non financial assets, and note 2.10 for the useful economic lives for each class of assets.
Impairment of debtors
The Company makes an estimate of the recoverable value of trade and other debtors. When assessing impairment of trade and other debtors, management considers factors including the current credit rating of the debtor, the ageing profile of the debtors and historical experience. Note 10 contains details of the net carrying amount of the debtors and any associated impairment provision.


4.


Employees

The average monthly number of employees, including directors, during the year was 14 (2023 - 18).

Page 6

 
EUROPA SCIENCE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

5.


Intangible assets




Other Intangibles
Computer software
Total

£
£
£



Cost


At 1 January 2024
255,000
87,396
342,396


Additions - internal
-
30,380
30,380



At 31 December 2024

255,000
117,776
372,776



Amortisation


At 1 January 2024
255,000
21,525
276,525


Charge for the year on owned assets
-
34,087
34,087



At 31 December 2024

255,000
55,612
310,612



Net book value



At 31 December 2024
-
62,164
62,164



At 31 December 2023
-
65,871
65,871



Page 7

 
EUROPA SCIENCE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

6.


Tangible fixed assets





Fixtures & fittings
Office equipment
Total

£
£
£



Cost or valuation


At 1 January 2024
29,016
60,907
89,923



At 31 December 2024

29,016
60,907
89,923



Depreciation


At 1 January 2024
27,357
57,857
85,214


Charge for the year on owned assets
415
2,165
2,580



At 31 December 2024

27,772
60,022
87,794



Net book value



At 31 December 2024
1,244
885
2,129



At 31 December 2023
1,659
3,050
4,709


7.


Debtors

2024
2023
£
£


Trade debtors
192,948
245,683

Amounts owed by group undertakings
231,018
-

Other debtors
8,579
192,715

Prepayments and accrued income
13,721
16,722

446,266
455,120



8.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
56,135
30,339

56,135
30,339


Page 8

 
EUROPA SCIENCE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

9.


Creditors: Amounts falling due after more than one year

2024
2023
£
£

Bank loans
20,000
60,000

20,000
60,000



10.


Loans


Analysis of the maturity of loans is given below:


2024
2023
£
£

Amounts falling due within one year

Bank loans
40,000
40,000


40,000
40,000

Amounts falling due 1-2 years

Bank loans
20,000
60,000


20,000
60,000

60,000
100,000


Page 9

 
EUROPA SCIENCE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

11.


Deferred taxation




2024


£






At beginning of year
(17,645)


Charged to profit or loss
1,572



At end of year
(16,073)

The provision for deferred taxation is made up as follows:

2024
2023
£
£


Accelerated capital allowances
(16,073)
(17,645)

(16,073)
(17,645)


12.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



300,000 (2023 - 300,000) Ordinary Shares of £0.01 each
3,000
3,000
2,000 (2023 - 2,000) B Ordinary Shares of £0.01 each
20
20

3,020

3,020



13.


Commitments under operating leases

At 31 December 2024 the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2024
2023
£
£


Not later than 1 year
26,000
26,000

Later than 1 year and not later than 5 years
-
26,000

26,000
52,000

Page 10

 
EUROPA SCIENCE LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

14.


Related party transactions

During the year, the directors received dividends of £Nil (2023: £Nil).
During the year, dividends of £Nil (2023: £Nil) were paid to the parent company Europa Science Holdings Ltd.


15.


Controlling party

The company was controlled by the parent company Europa Science Holdings Ltd by virtue of its 100% shareholding. On 30 January 2024 the controlling parent company was transferred from Europa Science Group Ltd.
 
Page 11